Introducing our Anti-Mouse CD247/CD3Z Polyclonal Antibody – a powerful tool for your biotech research needs.
This polyclonal antibody is specifically designed to target CD247/CD3Z, a key protein involved in T cell activation and signaling. It is a crucial component of the T cell receptor (TCR) complex, essential for the recognition and response to foreign antigens.
Our Anti-Mouse CD247/CD3Z Polyclonal Antibody is highly sensitive and specific, allowing for accurate detection and analysis of CD247/CD3Z in various samples. It has been extensively validated for use in a wide range of applications, making it an ideal choice for researchers in the field of immunology, cancer biology, and infectious diseases.
One of the main applications of this antibody is in flow cytometry, where it can be used for the identification and characterization of T cells in different stages of development and activation. It can also be used in immunohistochemistry to visualize the expression and localization of CD247/CD3Z in tissue samples.
In addition, our Anti-Mouse CD247/CD3Z Polyclonal Antibody has been proven to be effective in Western blotting, allowing for the detection of CD247/CD3Z in cell lysates and tissue homogenates. This can provide valuable insights into the expression levels and post-translational modifications of CD247/CD3Z in different cell types and conditions.
Furthermore, this antibody has been successfully used in various experimental settings, including studies on autoimmune diseases, viral infections, and cancer immunotherapy. Its high specificity and sensitivity make it a valuable tool for understanding the role of CD247/CD3Z in these disease processes.
In summary, our Anti-Mouse CD247/CD3Z Polyclonal Antibody is a reliable and versatile tool for investigating the function and expression of CD247/CD3Z in various biological systems. With its exceptional performance and wide range of applications, it is a must-have for any biotech research laboratory. Order now and take your research to the next level.
There are no reviews yet.